Cell free nucleic acids as diagnostic and prognostic marker in leukemia
SummaryNucleic acids in circulation, called cell free DNA (cfDNA) and cell free RNA (cfRNA), have recently been analyzed as suitable diagnostic and prognostic markers in cancer. There have also been several reports about the role of this type of marker in leukemia. The relevant literature was identified by a  PubMed search (2000–2017) of English-language literature using the terms “cell free DNA”, “Leukemia” and Micro-RNA. Many quantitative and qualitative cfDNA biomarkers including copy number alteration, mutation, LOH and micro-RNA deregulated expression have been investigated in differ...
Source: Memo - Magazine of European Medical Oncology - September 20, 2017 Category: Cancer & Oncology Source Type: research

What ’s new in chemotherapy for non-small cell lung cancer?
SummaryThe last few years have seen an explosion of novel treatment options for patients diagnosed with lung cancer, mostly for those with stage  IV non-small cell lung cancer. On the one hand, this was due to the development of modern diagnostic tools permitting accurate molecular diagnoses leading to the identification of several oncogenic driver mutations which can be therapeutically targeted. On the other hand, the advent of immunothera py in medical oncology in general, but in thoracic oncology in particular, has changed the treatment landscape first in second-line systemic treatment, but recently also in first-l...
Source: Memo - Magazine of European Medical Oncology - September 12, 2017 Category: Cancer & Oncology Source Type: research

An Austrian view of the 2017 consensus for the treatment of early breast cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 12, 2017 Category: Cancer & Oncology Source Type: research

New chemotherapies in gastric adenocarcinoma
SummaryChemotherapy is still the most important component of systemic therapy in gastric cancer. It is not replaced by targeted agents so far. Novel chemotherapies like 5 ‑fluorouracil (5FU) prodrugs are applied. Agents such as nanoliposomal irinotecan or nanoparticle albumin-bound paclitaxel are still under investigation. In patients overexpressing the epithelial growth factor receptor 2 (HER2), the addition of trastuzumab to classical chemotherapy improves overal l survival (OS) substantially and in second line setting the monoclonal antibody ramucirumab shows single agent activity as well as activity in combination wi...
Source: Memo - Magazine of European Medical Oncology - September 7, 2017 Category: Cancer & Oncology Source Type: research

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
SummaryDespite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a  devastating 5‑year overall survival of only 4–5%. Indeed, long-term survival was not affected by the introduction of new systemic cytotoxic chemotherapies which remain the key cornerstone in the treatment of metastatic PDAC. In the first-line setting, FOLFIRINOX based upon the results of the P RODIGE/ACCORD trial and gemcitabine with albumin-bound paclitaxel (GNP) based upon the MPACT trial have both been approved as therapeutic options for patients with no significant comorbid...
Source: Memo - Magazine of European Medical Oncology - September 7, 2017 Category: Cancer & Oncology Source Type: research

Development of chemotherapeutics in oncology: is there anything new?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 7, 2017 Category: Cancer & Oncology Source Type: research

Novel therapeutics in supportive cancer treatment
SummaryWith constantly improving cancer therapies, patient ’s quality of life, the management of potential side effects and treatment-related symptoms have also made considerable progress. Chemotherapy-induced nausea and vomiting (CINV) still constitutes a major problem for many patients. New developments in the field allow a more comfortable administra tion of guideline-based antiemetic therapy and may further improve the control of nausea. Therapeutic options for the cancer anorexia–cachexia syndrome (CACS), common in advanced cancers, are still limited and hampered by numerous side effects. Among t...
Source: Memo - Magazine of European Medical Oncology - September 1, 2017 Category: Cancer & Oncology Source Type: research

Chemotherapies and future directions in metastatic colorectal cancer
SummarySubstantial progress has been achieved in the management of metastatic colorectal cancer (mCRC) over the last two decades. The overall survival has increased from 10  months to more than 30 months. These improvements are due to the integration of multiple cytotoxic agents and targeted therapies, as well as individualized treatment strategies using molecular and clinical factors. More specific, molecular characteristics such as RAS mutation status and clinical factors such as performance status, tumor burden, tumor-related symptoms and comorbidities are crucial in selecting treatment strategies. Here I ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2017 Category: Cancer & Oncology Source Type: research

New chemotherapies in breast cancer
SummaryIn the era of targeted therapies and immunotherapy for cancer, the focus in breast cancer (BC) research has shifted away from classical chemotherapy. Many BC patients, however, still need chemotherapy and thus benefit from the development of new chemotherapeutic agents or regimens. In the past decade, the approval of eribulin and trastuzumab emtansine (T-DM1) have been important advances in this regard. Improved ways of delivery of paclitaxel, anthracyclines, and vinorelbine have also had a  considerable clinical impact. Finally, optimizing the use of well-known drugs, such as carboplatin, capecitabine, or adju...
Source: Memo - Magazine of European Medical Oncology - August 22, 2017 Category: Cancer & Oncology Source Type: research

Renal insufficiency in patients with multiple myeloma
SummaryRenal insufficiency in patients with multiple myeloma represents a  major challenge for the treating physician. In patients with etiologically unclear renal failure it is important to consider multiple myeloma as a possible cause of such renal failure. The diagnosis and treatment of these patients is interdisciplinary, in cooperation with hemato-oncologists, radi ologists, nephrologists and intensive care specialists. The main goal of all treatment methods is the rapid reduction of pathological free light chains in the serum, resulting in an improvement of renal function. Equally important is the avoidance...
Source: Memo - Magazine of European Medical Oncology - August 21, 2017 Category: Cancer & Oncology Source Type: research

Highlights from the 2017 St. Gallen Breast Cancer Consensus
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 21, 2017 Category: Cancer & Oncology Source Type: research

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
SummaryThe era of antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway has become a  mainstay in the treatment of metastatic renal cell carcinoma (mRCC), showing primary responses in 65–70% of patients. Nevertheless, most of those patients progress to angiogenesis inhibitors over time due to different modes of resistance (adaptive and intrinsic). Both in vitro and in vivo analys es provided evidence that PD-L1 upregulation in hypoxia conditions is dependent on hypoxia-inducible factor (HIF)-2alpha and is associated with an overexpression of VEGF. Thus, additional blockad...
Source: Memo - Magazine of European Medical Oncology - August 11, 2017 Category: Cancer & Oncology Source Type: research

Congress Report ESMO 2017
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 7, 2017 Category: Cancer & Oncology Source Type: research

Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia
SummaryAt the therapeutic intersection between children and older adults, the treatment of adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) poses unique challenges due to their dismal outcome. In this brief review, we report on the biological features, clinical characteristics and treatment results of a  pediatric and AYAs cohort of ALL and AML, treated in our department over a 15-year period. Additionally, we review the recent insights into disease biology, clinical, cytogenetic and molecular characteristics and differences between pediatric patients and...
Source: Memo - Magazine of European Medical Oncology - August 2, 2017 Category: Cancer & Oncology Source Type: research

ASCO update – what is new in the systemic treatment of advanced soft tissue sarcomas?
This article provides a brief overview of the standard systemic treatment options in advanced STS and a summary of the highlights of the STS trials presented at the American So ciety of Clinical Oncology (ASCO) annual meeting 2017. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 2, 2017 Category: Cancer & Oncology Source Type: research

Congress Report ASCO 2017
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 1, 2017 Category: Cancer & Oncology Source Type: research

Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
SummaryThe patient described here presented with relapsed multiple myeloma progressing after therapy with immunomodulatory agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib and carfilzomib). Eventually, the patient achieved an excellent response to the combination of panobinostat, bortezomib and dexamethasone, overcoming resistance to proteasome inhibitors and achieving a sustained VGPR (very good partial remission), which was consolidated with high-dose melphalan and autologous stem-cell transplantation. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 18, 2017 Category: Cancer & Oncology Source Type: research

New diagnostic tools for  breast cancer
SummaryImaging plays a  major role in the diagnosis, treatment, and follow-up of breast cancer. Findings that require further assessment will be detected both at screening and curative mammography. Most findings that are further worked up tend to yield benign diagnoses. Consequently, there is an ongoing search for new to ols to reduce recalls and unnecessary biopsies while maintaining or improving cancer detection rates. The clinically most promising methods in this respect are described and discussed in this review. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 28, 2017 Category: Cancer & Oncology Source Type: research

American Society of Hematology 2016 annual meeting
SummaryAt the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented.In diffuse large B ‑cell lymphoma (DLBCL), again, a more intensified treatment approach failed to improve patient survival. Moreover, and in contrast to indolent lymphoma, the use of obinutuzumab instead of rituximab (R) did not prove to be superior in DLBCL. However, data on lenalidomide maintenance, as well as da ta on novel agents in pr...
Source: Memo - Magazine of European Medical Oncology - June 19, 2017 Category: Cancer & Oncology Source Type: research

Notes from California – experts review the ASH meeting 2016 in San Diego
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 19, 2017 Category: Cancer & Oncology Source Type: research

Local therapies for breast cancer
SummaryDuring the San Antonio Breast Cancer Symposium in December 2016, the main topics were systemic treatment of breast cancer and molecular research. But several studies were also presented concerning local therapy: Surgical issues on evaluating resection margins, management of ductal carcinoma in situ (DCIS), surgical challenges after neoadjuvant therapy related to assessment of response or treatment of axillary lymph nodes, and studies about outcome after breast reconstruction and radiation therapy were discussed. In this short review, oral presentations of these topics are summarized. (Source: Memo - Magazine of Euro...
Source: Memo - Magazine of European Medical Oncology - June 7, 2017 Category: Cancer & Oncology Source Type: research

Is there progress in the treatment of high-risk myeloma?
SummaryTreatment of high-risk patients is a  major challenge in multiple myeloma (MM). Median survival rates of these patients remain poor at about 2 years and there were no major improvements with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). This resulted in a remarkable discrepancy in the treatment results of MM, with a significant proportion of patients achieving long-term progression-free survival of>10  years (or even cure) while in patients with aggressive disease no or only minor improvements have been achieved. Current consensus statements define hi...
Source: Memo - Magazine of European Medical Oncology - June 6, 2017 Category: Cancer & Oncology Source Type: research

Clinicopathological profile and treatment outcome of squamous cell carcinoma breast at a  tertiary cancer center in South India
ConclusionSCCB is a  rare subtype of breast cancer with no standard treatment approach. These are associated with poor prognosis and larger studies are needed to investigate different treatment options. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation: up-date from ASH 2016
SummaryAllogeneic hematopoietic stem cell transplantation (allo HSCT) offers a  potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e.&thi...
Source: Memo - Magazine of European Medical Oncology - June 1, 2017 Category: Cancer & Oncology Source Type: research

ASH Meeting 2016: developments in hemostaseology
SummaryDuring the annual meeting of the American Society of Hematology (ASH) in San Diego/California, novel developments in the field of hemostaseology were presented. Alternative treatment strategies besides factor replacement were discussed for patients with hemophilia. One of the highlights of the meeting in this year ’s plenary session was the presentation of successful adeno-associated virus mediated gene transfer in patients with hemophilia B leading to sustained elevation of factor IX:C (FIX:c). Other alternative treatment approaches in patients with hemophilia A may include bispecific antibodies mim...
Source: Memo - Magazine of European Medical Oncology - June 1, 2017 Category: Cancer & Oncology Source Type: research

Post San Antonio Breast Cancer Symposium
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 30, 2017 Category: Cancer & Oncology Source Type: research

News in AL Amyloidosis ASH 2016
SummaryAmyloidosis is a  rare but life-threatening protein misfolding disease. The early diagnosis and enrollment of patients into multicentre trials is of great importance, as is the need for intensive collaboration between multiple medical departments and experienced specialists. In the following review, the most intere sting abstracts from the annual American Society of Hematology (ASH) meeting in 2016 are presented. The topics include the limitations of established biomarkers in risk assessment and response evaluation, the introduction of a new biomarker, the comparison of different treatment sequences and th...
Source: Memo - Magazine of European Medical Oncology - May 24, 2017 Category: Cancer & Oncology Source Type: research

American Society of Hematology 2016 annual meeting
SummaryFor heterogeneous myelodysplastic syndromes (MDS), patient management is still a  challenge. Despite the progress achieved in recent years, there is need for improvement at least for specific situations such as failure of hypomethylating agents or in patients with thrombocytopenia or with anemia failing erythropoiesis stimulating agents. This review covers studies for MDS prese nted at the American Society of Hematology (ASH) 2016 annual meeting. New treatment approaches, for which results from phase 1/2 studies were reported, will now move into phase 3 and hopefully into clinical practice in the future. C...
Source: Memo - Magazine of European Medical Oncology - May 16, 2017 Category: Cancer & Oncology Source Type: research

Short review San Antonio 2016
SummaryThe San Antonio Breast Cancer Symposium 2016 featured all areas in the treatment of breast cancer. However, the meeting again showed that surgery remains the major column in the treatment of breast cancer. Various areas of development in the surgical management of breast cancer received significant attention in 2016 – sentinel lymph node (SLN) biopsy after neoadjuvant chemotherapy, radiotherapy after breast reconstruction and imaging strategies for the surgical treatment of breast cancer. In this short overview the most interesting presentations from the meeting are presented. (Source: Memo - Magazine of Europ...
Source: Memo - Magazine of European Medical Oncology - May 16, 2017 Category: Cancer & Oncology Source Type: research

Early stage breast cancer treatment and prognostic factors
SummaryDevelopments in early breast cancer presented at the 2016 San Antonio Breast Cancer Symposium included important studies on extending adjuvant endocrine therapy with aromatase inhibitors, the role of bisphosphonates, and evidence for molecular prognostic factors and circulating tumor cells in early stage breast cancer patients. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 25, 2017 Category: Cancer & Oncology Source Type: research

Primary signet cell carcinoma of the prostate: a  case report
SummaryPrimary signet cell carcinoma of the prostate is very rare histological variant and usually originates from the stomach, colon, and pancreas. This malignancy was first reported in 1979 and there have been case series with small numbers of patients and case reports in the literature. Signet cell carcinoma of the prostate has a poor outcome when compared to classic prostate adenocarcinoma. A  case of primary signet cell carcinoma of the prostate that was treated with maximal androgen deprivation therapy with zoledronic acid is reported. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 25, 2017 Category: Cancer & Oncology Source Type: research

SABCS 2016: systemic therapy for metastatic breast cancer
SummaryAt the 2016 San Antonio Breast Cancer Symposium, several interesting phase  II and phase III studies investigating systemic therapies for metastatic breast cancer were presented. The PrEGOC 0102 trial demonstrated that the combination of fulvestrant plus everolimus is safe and effective and could be an alternative to exemestane plus everolimus for selected patients with hormone-receptor positive, HER2-negative disease. The pan-PI3K inhibitor buparlisib showed some activity in combination with fulvestrant after failure of everolimus in the BELLE-3 trial. PIK3CA mutation detected in circulating tumor DNA (ct...
Source: Memo - Magazine of European Medical Oncology - April 4, 2017 Category: Cancer & Oncology Source Type: research

Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia
SummaryAcute lymphoblastic leukemia (ALL) forms a  heterogeneous group of disorders with a characteristic set of CD markers. Nowadays, these markers are used for the classification of hematopoietic malignancies and are a basis for diagnosis of leukemia. Unusual expression of CD markers as different immunophenotype of lymphoblasts is known as the aberrant expression of markers. The frequency of this phenomenon has been reported to be nearly 30% in different studies. Immunophenotype of precursor B‑cell leukemia involves the likely expression of myeloid CD markers (CD13 and CD33). In precursor T‑cell leukem...
Source: Memo - Magazine of European Medical Oncology - March 29, 2017 Category: Cancer & Oncology Source Type: research

Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
SummaryThe patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80  years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of bre ntuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1&...
Source: Memo - Magazine of European Medical Oncology - March 27, 2017 Category: Cancer & Oncology Source Type: research

Orbito-maxillofacial mesenchymal chondrosarcoma with intracranial invasion and lung metastasis
We report on a  patient who presented with swelling to the left side of the face accompanied by exophthalmos. Imaging studies revealed a large expansive heterogeneous mass encroaching on the sinonasal region. Following intravenous contrast administration revealed a lesion with moderate enhancement and involveme nt of the ipsilateral orbital cavity with intracranial invasion. The patient underwent tumor resection and a biopsy confirmed the presence of a mesenchymal chondrosarcoma. Additional treatment included radiation therapy and the patient is currently receiving palliative and supportive care fo...
Source: Memo - Magazine of European Medical Oncology - March 23, 2017 Category: Cancer & Oncology Source Type: research

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 22, 2017 Category: Cancer & Oncology Source Type: research

memo : Spectacular developments during the last decade from the Section Editors ’ point of view
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 13, 2017 Category: Cancer & Oncology Source Type: research

Milestones in advanced renal cell carcinoma
SummaryRenal cell carcinoma (RCC) is a common tumor that is largely refractory to cytotoxic agents. With the implementation of a multitude of novel therapies in the past 10  years, the overall survival of patients with advanced RCC has more than doubled. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 9, 2017 Category: Cancer & Oncology Source Type: research

To print or not to print
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 3, 2017 Category: Cancer & Oncology Source Type: research

Breast cancer milestones 2007 –2016
SummaryOver the past 10  years, enormous progress has been made in breast cancer (BC) treatment, leading to a substantial decline in BC mortality in Western countries. Although the following short review is necessarily incomplete, the discussion will highlight major achievements in the field. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 28, 2017 Category: Cancer & Oncology Source Type: research

Milestones in  Chronic Lymphocytic Leukemia
SummaryThe past 10  years have been an exciting ride for Chronic Lymphocytic Leukemia (CLL) aficionados. An overview of changes in management paradigms in CLL, ranging from insights into biology, via chemotherapy and chemoimmunotherapy to maintenance and novel drugs will be presented. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 27, 2017 Category: Cancer & Oncology Source Type: research

memo : Official journal of the OeGHO and CECOG
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 27, 2017 Category: Cancer & Oncology Source Type: research

Wclc 2016
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 14, 2017 Category: Cancer & Oncology Source Type: research

My personal highlights of ESMO 2016
This article summerizes the personal highlights of three medical oncologists in their respective areas of expertise. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 8, 2017 Category: Cancer & Oncology Source Type: research

Brentuximab vedotin in a  patient with enteropathy-associated T‑cell lymphoma of the small bowel
SummaryAs the prognosis of enteropathy-associated T ‑cell lymphoma is poor, innovative treatment options are called for, such as the anti-CD30 monoclonal antibody–drug conjugate brentuximab vedotin. The patient presented in this report was diagnosed with enteropathy-associated T‑cell lymphoma that affected the jejunum. Standard chemotherapy wit h CHOP induced complete remission, but the disease relapsed within 8 months, with the ileum as the site of relapse. Since further testing revealed CD30 positivity, treatment with brentuximab vedotin was started. After 18 cycles, the treatment had to be discontinu...
Source: Memo - Magazine of European Medical Oncology - February 6, 2017 Category: Cancer & Oncology Source Type: research

Milestones in the systemic treatment of lung cancer
SummarySeveral milestones in the systemic treatment of lung cancer have been reached. Combination chemotherapy of small cell lung cancer was the first of these milestones. The establishment of palliative chemotherapy in patients with advanced non-small cell lung cancer and of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer was another important milestone. Targeted therapies with angiogenesis inhibitors, EGFR inhibitors, and ALK inhibitors also advanced treatment. The clinical introduction of immune checkpoint inhibitors was the latest milestone. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 6, 2017 Category: Cancer & Oncology Source Type: research

Milestones in myeloma
SummaryThe field of myeloma has been very dynamic in the last 10  years. Indeed, in no other hematological malignancy has progress been so rapid. In Europe, five new myeloma drugs were approved in the 2‑year period during 2015–2016. This has already had a profound impact on the way we approach treatment of relapsed disease. In the near future, the results o f trials evaluating some of these very new substances in first-line treatment will be available and hopefully will show a further improvement of disease control over what has already been achieved with current upfront protocols. (Source: Memo - Ma...
Source: Memo - Magazine of European Medical Oncology - January 31, 2017 Category: Cancer & Oncology Source Type: research

Milestones in gastric cancer
SummaryGastric cancer incidence is decreasing in western countries in the last decades. During the last years diagnostic and therapeutic options in gastric cancer have improved substantially. The aim of this short review is to highlight the progress and setbacks in therapy of gastric cancer over the last 10 years and to set them into perspective. Back in 2006 optimal curative treatment was still under debate, palliative first line treatment was standard but no targeted therapy for gastric cancer was available. Second line treatment was indicated rarely if ever in gastric cancer patients and no data were published on phase ...
Source: Memo - Magazine of European Medical Oncology - January 31, 2017 Category: Cancer & Oncology Source Type: research

Milestones of the last 10  years
SummaryFor neuro-oncologists, much was accomplished in the last decade, including the establishment of the first standard of care (SOC) in this field of oncology. New treatment options boosted research in the whole field of neuro-oncology, as well clinical trials, translational and basic research. Accumulated data on molecular –genetic subgroups with distinct clinical outcomes in disease entities led to the establishment of new biomarkers and to the collaborative formulation of a new WHO classification of central nervous system tumors. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 25, 2017 Category: Cancer & Oncology Source Type: research

ASCO 2016 – update colorectal liver metastases
SummaryThis short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a  large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial grow...
Source: Memo - Magazine of European Medical Oncology - January 17, 2017 Category: Cancer & Oncology Source Type: research